Zevra Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Zevra Therapeutics, Inc. (ZVRA) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$200.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-05
- Zevra Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$100.00K.
- Zevra Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$100.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|
| 2026-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$200.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$100.00K 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $100.00K 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |